이뮤노포지㈜는 반감기 연장 플랫폼 기술 기반의 파이프라인을 보유한 신약개발 회사입니다.
Identification | Indication | Target | Discovery | Non-clinical | Phase I | Phase II | 비고 | |
---|---|---|---|---|---|---|---|---|
ELP Platform |
PF1801 | Polymyositis (PM)/ Dermatomyositis (DM) |
GLP-1*(Weekly) * Sarcopenia |
|
FDA ODD | |||
Duchenne Muscular Dystrophy (DMD) |
|
FDA ODD | ||||||
Inclusion Body Myositis (IBM) |
|
|||||||
Senile Sarcopenia |
|
|||||||
PF1804 | Cardiomyopathy(DMD), Heart Failure, Cystic Fibrosis |
VIP |
|
FDA ODD | ||||
PF1805 | Achondroplasia | CNP |
|
|||||
PF1806 | Short Bowel Syndrome (SBS) | GLP-2 (Weekly) |
|
|||||
PF1807 | Sarcopenia | GLP-1 (Monthly) |
|
|||||
PF1808 | ||||||||
PF1802 | Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease |
Undisclosed |
|
|||||
PF1803 | Osteoarthritis (OA) | OSCAR+ |
|
|||||
KF1601 | Drug Resistant Chronic Myeloid Leukemia (CML) |
BCR-ABL1 T315I |
|
FDA ODD |